Evidence map›Paper›PMID 26769715›Full record

ArticleNeuro-oncology2016

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases.

Michelle M Kim, Hemant Parmar, Yue Cao, Susan J Knox, Bryan Oronsky, Jan Scicinski, Theodore S Lawrence, Christopher D Lao

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. RRx-001 protects against cisplatin-induced toxicities.Journal of cancer research and clinical oncology · 2017
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michelle M KimUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Hemant ParmarUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Yue CaoUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Susan J KnoxUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Bryan OronskyUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Jan ScicinskiUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Theodore S LawrenceUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).
Christopher D LaoUniversity of Michigan, Ann Arbor, Michigan (M.M.K., H.P., Y.C., T.S.L., C.D.L.); Stanford University School of Medicine, Radiation Oncology, Stanford, California (S.J.K.); EpicentRx, Inc, Mountain View, California (B.O., J.S.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AzetidinesBrain NeoplasmsHumansMelanomaNitro CompoundsTreatment OutcomeAzetidinesNitro CompoundsRRx-001brain metastasesmelanomaradioresistanceradiosensitizerwhole brain radiotherapy

Identifiers

PMID26769715
PMCPMC4767246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.